XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.

XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.

Item
http://www.wikidata.org/entity/Q30368427
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesDNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk: a meta-analysis.Association Between Twelve Polymorphisms in Five X-ray Repair Cross-complementing Genes and the Risk of Urological Neoplasms: A Systematic Review and Meta-AnalysisXRCC1 Arg194Trp and Arg280His polymorphisms increase bladder cancer risk in Asian population: evidence from a meta-analysisPredictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer.Correlation between XRCC1 Arg399Gln genetic polymorphisms and susceptibility to bladder cancer: a meta-analysis.Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis.H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies.IL-4 and TNF-α Polymorphisms Are Associated with Risk of Multiple Superficial Tumors or Carcinoma in situ Development
P2860

XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.

Item
http://www.wikidata.org/entity/Q30368427
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@ast
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@en
type
label
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@ast
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@en
prefLabel
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@ast
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
XRCC1 codon 399 mutant allele: ...... patients on BCG immunotherapy
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921